An Update on the Long-Term Safety Experience of Ixekizumab: Results from the Psoriasis Clinical Development Program with More than 3 Years of Follow-up from 12 Clinical Trials and More Than 15000 Patient-Years of Exposure to Ixekizumab
Year: 2018
Type: article
Abstract: not available. Disclosures: Study sponsored by Eli Lilly & Company. Copyright 2018 SKIN
Authors: April Armstrong, Noah Agada, Wen Xu, Gaia Gallo
Institutions: University of Southern California, Eli Lilly (United States)
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: diamond
Funder: Eli Lilly and Company
OpenAlex ID: W2911276945